With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.
Shares in Lundbeck Inc. fell by 10% when the Danish drug maker announced its half yearly results on Aug. 8, with generic erosion keeping the company’s full-year guidance flat.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Adstiladrin sales hit €70m in first full year on the market
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.
Adstiladrin sales hit €70m in first full year on the market
Evaluate data show that biopharma companies raising cash in the smallest and largest categories of venture capital financings struggled to meet bars set in prior quarters.
